Invivyd CFO & Execs Buy Shares, Signaling Confidence Despite Volatile Market
Invivyd’s CFO and C‑suite buy 2.8 M zero‑cost options, signaling confidence in a rising share price amid volatility and a hopeful 2026 outlook for its NVD200 antibody pipeline.
3 minutes to read